Last reviewed · How we verify

Chronic Occlusive Peripheral Arterial Disease — Treatment Landscape & Competitive Intelligence

Chronic Occlusive Peripheral Arterial Disease (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic Occlusive Peripheral Arterial Disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Praxilene naftidrofuryl oxalate Merck Serono (originally Lipha) 5-HT2 receptor antagonist, Peripheral vasodilator 5-hydroxytryptamine receptor 2A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Chronic Occlusive Peripheral Arterial Disease
  2. Merck Serono (originally Lipha) · 1 drug in Chronic Occlusive Peripheral Arterial Disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic Occlusive Peripheral Arterial Disease:

Cite this brief

Drug Landscape (2026). Chronic Occlusive Peripheral Arterial Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-occlusive-peripheral-arterial-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing